Freshfields advises Evotec on acquisition of Central Glass Germany
Global law firm Freshfields Bruckhaus Deringer (‘Freshfields’) is advising publicly listed Evotec SE on the acquisition of Central Glass Germany GmbH from Japanese chemical manufacturing company Central Glass Co. Ltd.
Central Glass Germany is an EU GMP certified contract developer and manufacturer (CDMO) of active pharmaceutical ingredients with a drug substance manufacturing facility in Halle (Westphalia). Evotec SE is a life science company researching, developing and manufacturing highly effective therapeutics and is listed on the TecDAX and MDAX as well as on NASDAQ.
Freshfields is advising Evotec SE on the corporate and tax structuring of the transaction and negotiation of the share purchase agreement as well as on the negotiation of a new long-term lease agreement for the production facility.
The cross-practice Freshfields team was led by Partner Christoph H. Seibt (Lead) and Principal Associate Jil Rollmann (both Global Transactions, Hamburg) and included i.a.:
- Partner: Niko Schultz-Süchting (Real Estate, Hamburg), Alexander Schwahn (Tax, Hamburg)
- Counsel: Sascha Arnold (Regulatory, Hamburg)
- Principal Associates: Aljosha Barath (Intellectual Property, Hamburg), Tobias Franz (Tax, Hamburg)
- Associates: Vasco Ollero (Global Transactions, Hamburg), Daniel Extra (Real Estate, Hamburg), Jan Kothe (Tax, Hamburg)
Evotec SE is advised inhouse by General Counsel Christian Dargel.